Welcome to the Department of Health Care Services Welcome to Medi-Cal Welcome to the Department of Health Care Services

Medi-Cal Logo
Click to Sign Up for MCSS emails

Six Products Added to Antihemophilia Blood Factor List

February 10, 2017

Effective for dates of service on or after January 1, 2017, the following products have been added as benefits to be billed with HCPCS code J7199 (hemophilia clotting factor, not otherwise classified):

    Von Willebrand factor, recombinant, (Vonvendi), NDC 00944755102

    Von Willebrand factor, recombinant, (Vonvendi), NDC 00944755302

Effective for dates of service on or after January 1, 2017, the following products have been added as benefits to be billed with HCPCS code C9137 (injection, factor VIII [antihemophilic factor, recombinant] PEGylated, 1 I.U.):

    Antihemophilic factor (FVIII) recombinant, full length, PEGylated, NDC 00944462201

    Antihemophilic factor (FVIII) recombinant, full length, PEGylated, NDC 00944462301

    Antihemophilic factor (FVIII) recombinant, full length, PEGylated, NDC 00944462401

    Antihemophilic factor (FVIII) recombinant, full length, PEGylated, NDC 00944462501

Due to claims systems issues experienced on or after January 1, 2017, antihemophilia blood factor claims submitted to the Department of Health Care Services (DHCS) may have denied erroneously. Providers who experienced a denial for a claim that is compliant with current policy are instructed to rebill those claims with appropriate date(s) of service.

Manual replacement pages reflecting these changes will be released in a future Medi-Cal Update.